Published in Vopr Onkol on January 01, 1989
Hypothalamic mechanisms of ageing and of specific age pathology--II. on the sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in adaptive homestasis. Exp Gerontol (1979) 1.39
Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol (2004) 1.08
Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol (2003) 0.94
[Assessment of cancer morbidity and treatment for female genital tumors in St.Petersburg]. Vopr Onkol (1999) 0.88
Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology (1982) 0.84
Mammary tumors in HER-2/NEU mice are characterized by low content of estrogen receptors-alpha and absence of progesterone receptors. Bull Exp Biol Med (2003) 0.84
[Malignant tumors of the genitalia in girls]. Vopr Onkol (1986) 0.83
Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma (1997) 0.79
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy. Bull Exp Biol Med (2004) 0.78
Endocrine-metabolic criteria for distinguishing two pathogenetic types of breast cancer. Neoplasma (1977) 0.78
[Hormonal-metabolic pattern of postmenopausal females with new onset of diabetes mellitus type 2: the role of cancer and hereditary predisposition to diabetes]. Vestn Ross Akad Med Nauk (2013) 0.78
[Characteristics of dyslipidemia in cancer patients]. Vopr Onkol (1986) 0.77
Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy. J Steroid Biochem Mol Biol (2000) 0.77
[Relation of blood lipids and insulin to body fat content, body surface area and state of the subcutaneous fatty tissue in patients with breast and lung cancer]. Vopr Onkol (1985) 0.76
Hyperinsulinemia as a factor modifying sensitivity of endometrial carcinoma to hormonal influences. Eur J Gynaecol Oncol (1993) 0.76
Genotoxic factors associated with the development of receptor-negative breast cancer: potential role of the phenomenon of switching of estrogen effects. Exp Oncol (2006) 0.76
Hormone-metabolic status in moderately smoking breast cancer patients. Acta Oncol (1997) 0.76
Induction of the estrogen effect-switching phenomenon by ethanol and its correction. Neurosci Behav Physiol (2002) 0.76
Estrogen content and DNA unwinding in tumor and normal endometrial tissue of aging endometrial cancer patients. Mutat Res (1996) 0.75
[A decrease in body weight, cholesterol and blood sugar under the influence of phenformin (phenylbiguanide) in patients with cancer and atherosclerosis]. Vopr Onkol (1972) 0.75
[Correction of endocrine-metabolic disorders in oncologic patients. The effect of biguanides (phenformin and adebita), miskleron and diphenin]. Vopr Onkol (1975) 0.75
Professor Vladimir Dilman. Int J Obes Relat Metab Disord (1995) 0.75
[Adipose and lean body mass in obese pre- and post-menopausal patients with breast cancer: the modifying role of smoking]. Vopr Onkol (1994) 0.75
[Immunohistochemical study of the proliferation of breast cancer cells based on the expression of proliferating cell nuclear antigen (PCNA)]. Vopr Onkol (1998) 0.75
[Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy]. Vopr Onkol (2006) 0.75
[Family diabetes and its consequences in cancer patients]. Vopr Onkol (2013) 0.75
[Molecular biological and biochemical features of breast cancer]. Vestn Ross Akad Med Nauk (1998) 0.75
[Postoperative hormone therapy of breast cancer (analysis of overall survival)]. Vopr Onkol (1996) 0.75
[Morphologic changes in the ovaries in cancer of the uterine body]. Vopr Onkol (1971) 0.75
[Effect of tamoxifen on the content of cytoplasmic steroid hormone receptors of the tumor in patients with cancer of the corpus uteri]. Vopr Onkol (1989) 0.75
[The effect of tobacco smoke on the uterotropic and genotoxic effects of estrogens in the rat uterus]. Ross Fiziol Zh Im I M Sechenova (1997) 0.75
[Genetic polymorphism of steroidogenic enzymes and steroid receptor level in tumors of the reproductive system]. Vopr Onkol (2004) 0.75
[Estrogen receptors in primary breast neoplasms]. Vopr Onkol (1984) 0.75
[Breast cancer receptor status in smoking and diabetic patients]. Vopr Onkol (2005) 0.75
[Effectiveness of adjuvant hormone therapy in breast cancer]. Vopr Onkol (1996) 0.75
[Combined use of lymphography and hysterocervicography in cancer of the uterine corpus]. Vopr Onkol (1969) 0.75
[Evaluation of the effect of ovariectomy in patients with stage III breast cancer]. Vestn Khir Im I I Grek (1987) 0.75
[Steroid hormone receptors and survival in breast cancer patients]. Vopr Onkol (1986) 0.75
[The nature of hyperinsulinemia (insulin resistance) in endometrial carcinoma: of plasma levels of insulin and c-peptide]. Vopr Onkol (2000) 0.75
[Evaluation of ovarian status in women who received anti-tumor therapy in childhood and adolescence]. Vopr Onkol (2014) 0.75
[Induction by ethanol of 'phenomenon of switching estrogen effect' and its correction]. Ross Fiziol Zh Im I M Sechenova (2001) 0.75
[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects]. Vopr Onkol (2001) 0.75
[Hormonal-metabolic status of cancer patients with late-onset menopause]. Vopr Onkol (2003) 0.75
[The adjuvant hormonal therapy of breast cancer]. Vopr Onkol (1995) 0.75
[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma]. Vopr Onkol (2005) 0.75
[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer]. Vopr Onkol (1996) 0.75
[Comparative study of the proliferation (by detection of Ki-67 antigen) and activity of nucleolar organizer regions in breast cancer cells]. Vopr Onkol (1998) 0.75
[Parameters of estrogen expression in patients with endometrial tumors as prognostic signs of the effectiveness of neoadjuvant antitumor hormone therapy]. Vopr Onkol (1996) 0.75
[Specifics of metabolic disorders in patients with "hormone-associated neoplastic" syndromes]. Vopr Onkol (1996) 0.75
[Tamoxifen-induced progesterone receptors in breast tumors]. Vopr Onkol (1991) 0.75
[Comparative characteristics of hormonal status in patients with receptor-negative cancers of the breast and of the endometrium]. Vopr Onkol (2003) 0.75
[Gail's coefficient in breast cancer patients with respect to menstrual status, body mass and estrogen receptor pattern of tumor]. Vopr Onkol (2004) 0.75
[Microviscosity of erythrocyte membranes in breast cancer patients: connection with the receptor phenotype of the tumor]. Vopr Onkol (2014) 0.75
Effect of ethanol on uterotropic action of estrogens. Bull Exp Biol Med (2000) 0.75
[Effect of previous diabetes therapy on tumor receptor phenotype in breast cancer: comparison of metformin and sulphonylurea derivatives]. Vopr Onkol (2010) 0.75
[Adrenal steroids in patients with breast cancer and in women with age-related impaired glucose tolerance]. Vopr Onkol (1996) 0.75
[Endocrine-genotoxic switchings as promoter of main noninfectious diseases]. Vestn Ross Akad Med Nauk (2008) 0.75
[Effect of tobacco smoke on the level of estrogens and DNA in the rat uterus]. Ross Fiziol Zh Im I M Sechenova (1999) 0.75
[Gail coefficient as a risk factor and prognosticator for the course of breast cancer: correlation with hormonal and metabolic parameters and clinical and morphologic features]. Vopr Onkol (2008) 0.75
Effect of oxyprogesterone caproate, tamoxifen and their combination on the level of steroid hormone receptors in the tumor, and some parameters of the reproductive system in patients with endometrial cancer. Clin Exp Obstet Gynecol (1990) 0.75
[Metabolic effect of tobacco smoke and "switching" the estrogen effect: mechanism of increased genotoxicity]. Vestn Ross Akad Med Nauk (2001) 0.75
[Determination of the proliferative activity of breast cancer cells using 5-bromo-2'-deoxyuridine in vivo]. Vopr Onkol (1997) 0.75
[Clinical substantiation for removing pelvic lymph nodes in cancer of the uterus]. Akush Ginekol (Mosk) (1970) 0.75
[Estrogen-dependence of thyroid carcinoma: testing with estradiol preparations and tamoxifen]. Vopr Onkol (2008) 0.75
[Problems in the classification of cancer of the uterine body by stages]. Vopr Onkol (1966) 0.75
[Interrelationship between response to neoadjuvant hormone therapy and hormonal-metabolic status in breast cancer patients]. Vopr Onkol (2001) 0.75
[Progenotoxic shift in mammary adipose tissue (adipogenotoxicosis): association with clinical and biological characteristics of breast cancer]. Vopr Onkol (2008) 0.75
[Hormones in the pathogenesis and treatment of malignant ovarian tumors]. Vopr Onkol (1977) 0.75
Study of tobacco smoke influence on content of estrogens and DNA flow cytometry data in uterine tissue of rats of different age. Horm Metab Res (1999) 0.75
[Catechol estrogen excretion in women receiving estrogen replacement therapy]. Biull Eksp Biol Med (1999) 0.75
[Effect of progestin therapy on the level of cytoplasmic receptors in patients with cancer of the corpus uteri]. Vopr Onkol (1989) 0.75
[The effect of tolbutamide on blood cholesterol levels in tumor patients]. Vopr Onkol (1967) 0.75
[Hormonal and progenotoxic properties of mammary fat in pre- and postmenopausal cancer patients]. Vopr Onkol (2006) 0.75
[Decrease of testosterone level in blood of breast cancer patients of reproductive age after neoadjuvant chemotherapy]. Vopr Onkol (2012) 0.75
[Correlation of lymphocytic infiltration of tumor tissue with the hormonal and metabolic state in patients with breast cancer]. Vopr Onkol (1996) 0.75
[Specifics of reproductive disorders and hormonal sensitivity of tumors in patients with "hormone-related neoplastic syndrome"]. Vopr Onkol (1996) 0.75
[Use of aromatase and its inhibitors in dealing with different oncological pathologies other than breast cancer]. Vopr Onkol (2007) 0.75
[Inhibition of the growth of Ehrlich transplantable carcinoma in mice by antichorionic immune serum]. Vopr Onkol (1983) 0.75
[Clinico-morphological characteristics and results of treatment of endometrioid cystadenocarcinoma of the ovary]. Vopr Onkol (1983) 0.75
[Protocol of the 500th jubilee meeting of the Society of Oncologists, devoted to the theme of "Hormone-dependent tumors -- pathogenesis and therapy," May 12, 2014]. Vopr Onkol (2014) 0.75
[Lipid peroxidation in endometrial cancer tissue: connection with hormonal sensitivity and hormonal cancerogenesis]. Vopr Onkol (1996) 0.75
[Cancer of the corpus uteri as a manifestation of hypothalamic pathology]. Vopr Onkol (1967) 0.75
[Steroid hormone excretion and some metabolic indices in children with breast hyperplasia]. Vopr Onkol (1973) 0.75
Criteria of endometrial carcinoma sensitivity to hormone therapy: pathogenetic type of the disease and the tumor reaction to tamoxifen. Eur J Gynaecol Oncol (1993) 0.75
[Search for drugs which decrease the hypothalamic threshold of homeostatic inhibition. I. Results of studies of the product Agr-307. (1st conclusions)]. Agressologie (1971) 0.75
Content of 8-hydroxy-2-deoxyguanosine in steroid receptor-positive and receptor-negative breast cancer cells. Bull Exp Biol Med (2005) 0.75
Influence of tobacco smoke on DNA unwinding and uterotrophic effect of estrogens in rats. Cancer Lett (1998) 0.75
Modification of the uterotropic effect produced by estrogens in aging rats. Bull Exp Biol Med (2002) 0.75
[A study of the effect of tobacco smoke on the uterotropic effects of estrogens]. Biull Eksp Biol Med (1997) 0.75
[State of immunological reactivity in breast cancer patients receiving prednisolone treatment]. Vopr Onkol (1979) 0.75
Modification of uterotropic effect of estrogens by whole-body gamma-irradiation. Bull Exp Biol Med (2001) 0.75
[Switching off the estrogen effect and approaches to its correction]. Ross Fiziol Zh Im I M Sechenova (2003) 0.75
Expression of estrogen receptors-beta and aromatase activity in primary mammary gland tumors. Bull Exp Biol Med (2003) 0.75
[Hormonal status and the clinical course of ovarian cancer]. Akush Ginekol (Mosk) (1978) 0.75
[Effects of tamoxifen and oxyprogesterone caproate on steroid hormone receptors in tumors and indicators of reproductive homeostasis in patients with cancer of the uterine body]. Akush Ginekol (Mosk) (1988) 0.75
[Detection of substances lowering the hypothalamic threshold of homeostatic inhibition. III. Study of Agr 1240]. Agressologie (1977) 0.75
Study of the role of steroid receptors in human breast cancer. Neoplasma (1985) 0.75
[Summary insulin-like activity of the blood serum in breast cancer and in specific age-related pathology]. Vopr Onkol (1982) 0.75
[Relation of urinary excretion of cholesterol in cancer patients to certain hormonal-metabolic parameters and the effect of drugs on this relation]. Vopr Med Khim (1979) 0.75